Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightThe risks of death and experiencing MACE increase among patients with high GlycA levels.
📌 3 Maddede Bu Makale
Özet
Objective: Glycoprotein acetylation (GlycA), an emerging inflammatory biomarker, has been used as an indicator of cardiovascular disease. Ourresearch aimed to evaluate the correlation between GlycA and coronary artery disease (CAD) using coronary computed tomography angiography(CCTA).Methods: In the present study, a total of 342 patients were enrolled, and each of them underwent CCTA. The correlation between GlycA andmajor adverse cardiac events (MACE) was detected via Cox’s proportional hazards models. Based on differences in the GlycA level, patientswere categorized into three groups (T1, T2, and T3).Results: Compared with the group with the lowest GlycA level (T1), the group with the highest GlycA level (T3) exhibited stronger atheroscleroticpressure involving the extent of atherosclerotic plaque and risk of obstructive CAD. In addition, the patients in the T3 group had a greater chanceof experiencing MACE and higher all-cause mortality than those in the T1 group. Among patients without CAD who underwent CCTA, those withhigh GlycA levels experienced elevated atherosclerotic stress and heightened risk of MACE compared with those with low GlycA levels.Conclusion: These results suggest that serum GlycA is significantly associated with the long-term clinical results of patients with no known CADundergoing CCTA. The risks of death and experiencing MACE increase among patients with high GlycA levels.